Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, announced a partnership with MedGenome powered by human genomics, for rare disease patients.
The two companies will collaborate to combine patients' epidemiologic, phenotypic, and genomic data into custom disease registries aiming to enhance study design, support patient recruitment, and create standard control arms for advanced statistical models of treatment effect.
Some of the initial rare diseases that the Emmes/MedGenome partnership will address include hemophilia, Duchenne muscular dystrophy and muscular atrophies, and retinitis pigmentosa.
